Global Hospital Infection Therapeutics Market, By Therapeutics (Anti-Bacterial Drugs, Anti-Fungal Drugs, Anti-Viral Drugs, Others), Infections (Hospital Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, Other Hospital Infections) – Industry Trends and Forecast to 2030.
Hospital Infection Therapeutics Market Analysis and Size
According to the World Health Organization (WHO), for every 100 hospitalized patients, 10 in developed countries and 7 in developing countries acquire at least one healthcare-associated infection. Urinary tract infections are expected to have a significant share of the indications segment and grow significantly. The increasing number of patients with urinary tract infections and ongoing research and development on urinary tract infection treatment are attributed to the growth. Furthermore, the growing elderly population and the prevalence of hospital-acquired infections will drive overall market growth during the forecast period.
Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hospital Infection Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapeutics (Anti-Bacterial Drugs, Anti-Fungal Drugs, Anti-Viral Drugs, Others), Infections (Hospital Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, Other Hospital Infections)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc. (U.K.), AstraZeneca (U.K.), Johnson & Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), AbbVie Inc. (U.S.), Sanofi (France), Gilead Sciences, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Basilea Pharmaceutica Ltd. (Switzerland), Spero Therapeutics (U.S.), BioSpace (Canada), POLYPID (Israel), Novartis AG (Switzerland), Bellerophon Therapeutics (U.S.), Achilles Therapeutics plc. (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Hospital infection therapeutics refers to pharmaceutical drugs used to treat hospital nosocomial infections. These infections can occur in hospitals, nursing homes, rehabilitation centers, and other clinical settings and are typically treated with antiviral, antibacterial, and antifungal medications. Vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides, and tigecycline are antibacterial therapeutics inhibiting cell wall synthesis and protein synthesis. Caspofungin and Amphotericin B are antifungal therapeutics that help to prevent hospital-acquired pneumonia, urinary tract infections (UTIs), bloodstream infections, and surgical site infections.
Global Hospital Infection Therapeutics Market Dynamics
Drivers
- Rising prevalence of hospital-acquired diseases
One of the key factors driving the market growth is the rising prevalence of hospital-acquired diseases (HAD). Furthermore, the growing geriatric population, which is more susceptible to such ailments, is driving market expansion. As a result of the deterioration of hygiene facilities in hospitals and other healthcare institutions, hospital-acquired pneumonia and other infections have increased significantly, contributing to the rising demand for hospital infection therapeutics.
- Rising prevalence of infections
According to data published by the New York State Department of Health in November 2019, approximately 160 New York hospitals reported 1,139 colon SSIs out of 19,732 procedures in 2018, resulting in a rate of 5.8 infections per 100 procedures. According to the same source, approximately 15,310 cases of clostridioides difficile infections (CDI) were reported in acute care hospitals in New York in 2018. The high prevalence of hospital-acquired infections is expected to significantly increase the demand for treatment therapies and support the market growth during the forecast period.
Opportunities
- Rising R&D initiatives
The key market players are engaged in extensive R&D initiatives for the development and indication expansion of their already approved HAI treatments. For instance, the FDA approved Allergan plc's supplemental New Drug Application (sNDA) in February 2018, expanding the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.
Restraints/Challenges
- High cost of clinical trials
Increasing the incidence of treatment-emergent resistance, significant investment required due to high attrition rates in clinical trials, and changing reimbursement policies hampered global market growth.
This hospital infection therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hospital infection therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Hospital Infection Therapeutics Market
The COVID-19 pandemic has increased exponentially in clinical trials searching for new therapies to treat the disease. Clinical trials involving therapeutics have gradually decreased since their peak in April 2020. This could be due to the negative outcomes of therapeutic clinical trials and the availability of vaccines on the market. Numerous drugs can be used to treat COVID-19 in and out of the hospital. One of the most important factors to consider when developing COVID-19 treatments is how well they work against existing and emerging SARS-CoV-2 variants. Treatments that are effective against one version of the virus may not be effective against another.
Global Hospital Infection Therapeutics Market Scope
The hospital infection therapeutics market is segmented on the basis of therapeutics, and infections. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapeutics
- Antibacterial Drugs
- Antifungal Drugs
- Antiviral Drugs
- Others
Infections
- Hospital Acquired Pneumonia
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Surgical Site Infections
- Other Hospital Infections
- Pneumonia
- Surgical Site Infections
Hospital Infection Therapeutics Market Regional Analysis/Insights
The hospital infection therapeutics market is analysed and market size insights and trends are provided by country, therapeutics, and infections as referenced above.
The countries covered in the hospital infection therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the hospital infection therapeutics market due to the increasing occurrences of chronic disorders, the rising prevalence of the geriatric population, and the growing number of research and development activities.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the development of healthcare infrastructure and surging levels of investment for the growth of the healthcare system.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The hospital infection therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hospital infection therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hospital infection therapeutics market. The data is available for historic period 2011-2021.
Competitive Landscape and Hospital Infection Therapeutics Market Share Analysis
The hospital infection therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hospital infection therapeutics market.
Some of the major players operating in the hospital infection therapeutics market are:
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc. (U.K.)
- AstraZeneca (U.K.)
- Johnson & Johnson Services, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Sanofi (France)
- Gilead Sciences, Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Basilea Pharmaceutica Ltd. (Switzerland)
- Spero Therapeutics (U.S.)
- BioSpace (Canada)
- POLYPID (Israel)
- Novartis AG (Switzerland)
- Bellerophon Therapeutics (U.S.)
- Achilles Therapeutics plc. (U.K.)
SKU-